Exploring the Potential Drug Target ATP6V0E1 (M9.2) in the Context of Cancer Treatment

Target Name: ATP6V0E1

NCBI ID: G8992

ATP6V0E1

Exploring the Potential Drug Target ATP6V0E1 (M9.2) in the Context of Cancer Treatment

Introduction

ATP6V0E1 (M9.2), also known as ALX148, is a drug candidate targeting the protein ATP6V0E1 (M9.2) in cancer treatment. Developed by GDC-0649, it is an antibody with a unique mechanism of action. Cancer drugs exert anti-tumor effects by inhibiting ATP6V0E1-mediated cell cycle proliferation. ATP6V0E1 is expressed in a variety of cancer types, including lung cancer, liver cancer, breast cancer, etc. This article will discuss in detail the role, mechanism and drug target properties of ATP6V0E1 in cancer treatment.

Mechanism of action of ATP6V0E1

ATP6V0E1 is a transcription factor involved in regulating biological processes such as cell cycle, DNA replication and apoptosis. Studies have shown that ATP6V0E1 is up-regulated in various cancer types and is closely related to tumor occurrence and development. Activation of ATP6V0E1 leads to cell cycle proliferation and promotes tumor initiation and progression. Inhibiting ATP6V0E1 activity can significantly inhibit the growth and spread of tumor cells.

Drug target properties of ATP6V0E1

The role of ATP6V0E1 in tumor treatment makes it a potential drug target. Through immunohistochemical analysis of ATP6V0E1 expression groups, the researchers found that individuals with ATP6V0E1 expression were significantly associated with tumor progression and invasion. In addition, the survival rate of patients with ATP6V0E1-positive tumors was significantly lower than that of patients with ATP6V0E1-negative tumors, indicating that ATP6V0E1 plays an important role in tumor treatment.

Research on the mechanism of action

As a transcription factor, ATP6V0E1 plays a key role in cancer treatment by inhibiting the growth of tumor cells by regulating the cell cycle. Activation of ATP6V0E1 leads to cell cycle proliferation, which is the basis for tumor cell growth and spread. Inhibiting ATP6V0E1 activity can block cell cycle proliferation, thereby inhibiting the growth and spread of tumor cells.

Pharmacokinetic studies

Pharmacokinetics is the biochemical process that studies the absorption, distribution, metabolism and excretion of drugs in the body. Research shows that ATP6V0E1 has better water solubility and lower protein binding rate, which is beneficial to the rapid absorption and distribution of drugs in the body. In addition, ATP6V0E1 has a longer half-life in the body, which can extend the half-life of the drug in the body and reduce the dose dependence of the drug.

Clinical application prospects

ATP6V0E1, as an anti-tumor drug, has broad application prospects in clinical trials. First, ATP6V0E1 can be used to treat a variety of cancers, including lung cancer, liver cancer, breast cancer, etc. Secondly, ATP6V0E1 has good pharmacokinetic properties and can achieve a good dose-effect relationship. In addition, ATP6V0E1 has good safety and tolerability and can reduce drug-related toxic and side effects.

in conclusion

As an anti-tumor drug with a unique mechanism of action, ATP6V0E1 has broad application prospects in inhibiting the growth and spread of tumor cells. By inhibiting ATP6V0E1-mediated cell cycle proliferation, ATP6V0E1 can significantly inhibit the growth and spread of tumor cells. ATP6V0E1 has good pharmacokinetic properties and safety performance, providing a potential drug target for tumor treatment. In the future, ATP6V0E1 is expected to become a commonly used anti-tumor drug in clinical practice, bringing new hope to the treatment of tumor patients.

Protein Name: ATPase H+ Transporting V0 Subunit E1

Functions: Subunit of the V0 complex of vacuolar(H+)-ATPase (V-ATPase), a multisubunit enzyme composed of a peripheral complex (V1) that hydrolyzes ATP and a membrane integral complex (V0) that translocates protons (PubMed:33065002). V-ATPase is responsible for acidifying and maintaining the pH of intracellular compartments and in some cell types, is targeted to the plasma membrane, where it is responsible for acidifying the extracellular environment (By similarity)

The "ATP6V0E1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ATP6V0E1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets